APA

Klitgaard H., Matagne A., Nicolas J., Gillard M., Lamberty Y., De Ryck M., Kaminski R. M., Leclercq K., Niespodziany I., Wolff C., Wood M., Hannestad J., Kervyn S. & Kenda B. (20160818). Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. : Epilepsia.

Chicago

Klitgaard Henrik, Matagne Alain, Nicolas Jean-Marie, Gillard Michel, Lamberty Yves, De Ryck Marc, Kaminski Rafal M, Leclercq Karine, Niespodziany Isabelle, Wolff Christian, Wood Martyn, Hannestad Jonas, Kervyn Sophie and Kenda Benoit. 20160818. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. : Epilepsia.

Harvard

Klitgaard H., Matagne A., Nicolas J., Gillard M., Lamberty Y., De Ryck M., Kaminski R. M., Leclercq K., Niespodziany I., Wolff C., Wood M., Hannestad J., Kervyn S. and Kenda B. (20160818). Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. : Epilepsia.

MLA

Klitgaard Henrik, Matagne Alain, Nicolas Jean-Marie, Gillard Michel, Lamberty Yves, De Ryck Marc, Kaminski Rafal M, Leclercq Karine, Niespodziany Isabelle, Wolff Christian, Wood Martyn, Hannestad Jonas, Kervyn Sophie and Kenda Benoit. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. : Epilepsia. 20160818.